- Nachrichtendetail
-
16.05.2024 08:18:12 - dpa-AFX: *AZN : PHASE III TRIAL OF SIPAVIBART ANTIBODY MEETS MAIN GOAL IN PREVENTING COVID-19 IN IMMUNOCOMPROMISED PATIENT
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
ASTRAZENECA PLC DL-,25 | 886455 | Frankfurt | 146,900 | 04.06.24 21:58:41 | +1,500 | +1,03% | 0,000 | 0,000 | 145,350 | 146,900 |
